ECTRIMS 2023 | Detection of CNS-reactive antibodies using iPSC-derived antigen based platform

Amandine Mathias, PhD, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland, discusses an ambitious project focusing on a prospective cohort of patients with an array of CNS disorders. Researchers aimed to validate the use of an induced pluripotent stem cells (iPSCs)-derived antigen based platform as a mechanism for detecting naturally presenting central nervous system (CNS) antigens. They analyzed clinical, radiological, and laboratory data, enrolling both patients with definitive autoimmune diagnoses and those with probable symptoms, especially those highly indicative of antibody involvement. Through this approach, the team managed to validate the ability of their model to identify the same commonly detected antibodies as in standard laboratory tests. Furthermore, they discovered novel auto-antibodies in up to 30% of probable autoimmune encephalitis patients and approximately 20% of NMOSD patients. Even within the MS patient group, 8-12% showcased astrocyte/neuron-reactive antibodies. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen dical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.